ArticleJournal of translational internal medicine2026
Inflammation, metabolism, and aging in heart failure with preserved ejection fraction: Mechanisms and treatment perspectives.
Article in Journal of translational internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Low serum complement C3 levels are associated with all-cause mortality in Chinese centenarians: a prospective cohort study.Frontiers in immunology · 2026Article
- Perimenopause as a potential window of cardiometabolic remodeling in heart failure with preserved ejection fraction: a missed opportunity for prevention.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure with preserved ejection fraction (HFpEF) is an increasingly prevalent clinical syndrome with limited effective therapies, representing a major unmet need in cardiovascular medicine. A comorbidity-driven systemic proinflammatory state, together with coronary microvascular endothelial inflammation, has emerged as a central paradigm in HFpEF pathogenesis. Accumulating evidence over the past decade has highlighted the extensive crosstalk between inflammation, metabolic dysregulation, and aging-related processes. In this review, we summarize key advances defining the roles of systemic and microvascular inflammation, metabolic abnormalities, and cellular senescence, and integrate these findings into an interconnected inflammation-metabolism-aging axis in HFpEF. We further discuss the current clinical and emerging preclinical therapeutic strategies targeting these pathways. By linking mechanistic insights with translational perspectives, this review provides a conceptual framework to guide precise therapeutic development for this complex and heterogeneous syndrome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.